Afternoon Session Opening: Jim Dahl, Partnership for Safe Medicines
•
0 likes•2,012 views
IFPMA-TFDA Workshop on Couterfeit Medicines ‘Integrated Approach Against Fake Medicines’ On 6th February 2015 At Taipei International Convention Center Taipei, Taiwan
Report
Share
Report
Share
Download to read offline
Recommended
Optimum Dry Ice Blasting Food Conveyor Chains
Dry ice blasting of food processing conveyor chains.
www.optimumdryiceblasting.co.uk
#dryiceblasting
30. Dr. Jaap Venema - Abbvie
30. Dr. Jaap Venema - AbbvieInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This document discusses regulatory and clinical perspectives on the interchangeability of biologicals and biosimilars. It notes that while generics are considered to be therapeutically equivalent, biosimilars are similar but not identical to the reference product. Regulators do not generally determine a biosimilar to be interchangeable without additional clinical evidence from switching studies demonstrating equivalent safety and efficacy when switching between the biosimilar and reference product. The clinical considerations around switching studies and their design are complex given the nature of biological products.Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...
Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 1: Current Regulatorz Landscape & Initiatives Against Fake Medicines
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanOpening Session - Cyntia Genole, IFPMA
Opening Session - Cyntia Genole, IFPMAInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanSession 4: Domenico Di Giorgio AIFA Italy / SPOC model cooperation against co...
Session 4: Domenico Di Giorgio AIFA Italy / SPOC model cooperation against co...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanSession 4: Sheuan Lee, International Council of Nurses (ICN) / Practices and ...
Session 4: Sheuan Lee, International Council of Nurses (ICN) / Practices and ...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 3: Practices and Technologies for Prevention, Detection, Control and Monitoring of Fake Medicines.
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanThe Complex Journey of a Vaccine
The Complex Journey of a VaccineInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This document is comprised of copyright notices from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) spanning the years 2014 through 2018, suggesting it contains content owned by IFPMA over those years. No other substantive information is provided in the document.International Psoriasis Council, Steve O'Dell
International Psoriasis Council, Steve O'DellInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document provides an overview of the International Psoriasis Council (IPC) and their partnership with ILDS and IFPA to execute the Global Psoriasis Atlas project. The IPC is a nonprofit organization comprised of the world's leading experts in psoriasis. They aim to advance knowledge of psoriasis and enhance patient care through research, education, and clinical practice guidelines. The document notes that worldwide prevalence and incidence of psoriasis is poorly understood currently. The Global Psoriasis Atlas project aims to address this through collecting epidemiological data on psoriasis prevalence, burden, and natural history across countries to inform policy and improve care.Recommended
Optimum Dry Ice Blasting Food Conveyor Chains
Dry ice blasting of food processing conveyor chains.
www.optimumdryiceblasting.co.uk
#dryiceblasting
30. Dr. Jaap Venema - Abbvie
30. Dr. Jaap Venema - AbbvieInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This document discusses regulatory and clinical perspectives on the interchangeability of biologicals and biosimilars. It notes that while generics are considered to be therapeutically equivalent, biosimilars are similar but not identical to the reference product. Regulators do not generally determine a biosimilar to be interchangeable without additional clinical evidence from switching studies demonstrating equivalent safety and efficacy when switching between the biosimilar and reference product. The clinical considerations around switching studies and their design are complex given the nature of biological products.Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...
Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 1: Current Regulatorz Landscape & Initiatives Against Fake Medicines
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanOpening Session - Cyntia Genole, IFPMA
Opening Session - Cyntia Genole, IFPMAInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanSession 4: Domenico Di Giorgio AIFA Italy / SPOC model cooperation against co...
Session 4: Domenico Di Giorgio AIFA Italy / SPOC model cooperation against co...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanSession 4: Sheuan Lee, International Council of Nurses (ICN) / Practices and ...
Session 4: Sheuan Lee, International Council of Nurses (ICN) / Practices and ...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 3: Practices and Technologies for Prevention, Detection, Control and Monitoring of Fake Medicines.
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanThe Complex Journey of a Vaccine
The Complex Journey of a VaccineInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This document is comprised of copyright notices from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) spanning the years 2014 through 2018, suggesting it contains content owned by IFPMA over those years. No other substantive information is provided in the document.International Psoriasis Council, Steve O'Dell
International Psoriasis Council, Steve O'DellInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document provides an overview of the International Psoriasis Council (IPC) and their partnership with ILDS and IFPA to execute the Global Psoriasis Atlas project. The IPC is a nonprofit organization comprised of the world's leading experts in psoriasis. They aim to advance knowledge of psoriasis and enhance patient care through research, education, and clinical practice guidelines. The document notes that worldwide prevalence and incidence of psoriasis is poorly understood currently. The Global Psoriasis Atlas project aims to address this through collecting epidemiological data on psoriasis prevalence, burden, and natural history across countries to inform policy and improve care.IFPA Psoriasis Presentation
IFPA Psoriasis PresentationInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA Geneva Pharma Forum on 9 May 2014
Bringing Psoriasis into the Light
International Federation of Psoriasis Associations
Barbra BohannanIFPMA: From Manufacturing to the Vaccinee – the Complex Journey of a Vaccine
IFPMA: From Manufacturing to the Vaccinee – the Complex Journey of a Vaccine International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
David K. Robinson, Ph. D. Vice President, Biologics Head and Executive Director, Biologics and Vaccines CMC Regulatory Merck & Co, Inc.
Presenting on behalf of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) WCBP CASS, Washington DC, USA January 2014Session 4: Bejon Misra Partnership for Safe Medicines (PSM) INDIA /
Session 4: Bejon Misra Partnership for Safe Medicines (PSM) INDIA / International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanSession 4 Sabine Walser Council of Europe / Legal framework necessary for eff...
Session 4 Sabine Walser Council of Europe / Legal framework necessary for eff...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanManaement of Psoriasis in Low Income Countries
Manaement of Psoriasis in Low Income CountriesInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA Geneva Pharma Forum on 9 May 2014
Bringing Psoriasis into the Light
Presentation of Professor Mahira Hamdy El Sayed
Dermatology and Venereology, Ain Shams UniversitySession1: Patrick Deboyser, European Union
Session1: Patrick Deboyser, European UnionInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 1: Current Regulatory Landscape & Initiatives Against Fake Medicines
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanPeter Hotez, Baylor College of Medicine
Peter Hotez, Baylor College of MedicineInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
30 November 2016, Washington DC
IFPMA Assembly 2016: Global Health V.2.0 Challenges in a Changing WorldSession 2: Mike Rose, Johnson & Johnson / Serialization and Traceability GS1 ...
Session 2: Mike Rose, Johnson & Johnson / Serialization and Traceability GS1 ...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 2: Supply Chain Integrity
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanSession 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...
Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanBringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
Bringing Psoriasis into the Light, Kim kjoeller, Leo PharmaInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document discusses psoriasis, a chronic skin condition affecting over 125 million people worldwide. Psoriasis causes thickened, red, scaly skin patches that often itch and bleed. It can also cause joint pain and increase risks for other health issues. The document outlines pharmaceutical company efforts to develop new drug treatments for psoriasis, including topical treatments, biologics, and oral medications currently in clinical trials. It emphasizes the need for comprehensive care that coordinates treatment from specialists and considers patients' needs to best manage psoriasis as a chronic condition.Session 2: Scott Kammer, Rx360
Session 2: Scott Kammer, Rx360 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 2: Supply Chain Integrity
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanSession 3: Ivan Ho Pfizer / Counterfeit Medicines Threat to Patient Health an...
Session 3: Ivan Ho Pfizer / Counterfeit Medicines Threat to Patient Health an...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 3: Practices and Technologies for Prevention, Detection, Control and Monitoring of Fake Medicines
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan13 carlo pini superior institute of italy
13 carlo pini superior institute of italyInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Latin Amercia Conference - Biotherapeutic Medicines
Sharing Experiences and Best Practices
Lima, Peru,
20 November 201315. Elki Sollenbring - Uppsala Monitoring Centre
15. Elki Sollenbring - Uppsala Monitoring CentreInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Wednesday, 20 November, 2013
Latin America Biotherapeutic Conference Day 221. Maurice Mayrides - Esperantra
21. Maurice Mayrides - EsperantraInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Maurice Mayrides discusses the importance of the patient voice in regulating biosimilars. He summarizes the value of biosimilars from different stakeholder perspectives including patients, clinicians, industry, and governments. While biosimilars offer potential cost savings and innovation, patients will only feel comfortable with interchangeability if regulations are sophisticated and harmonized internationally. Regulations must ensure safety, efficacy, and quality to gain patient trust especially in emerging markets and lower-resource countries. Continued advocacy is needed to refine regulations and gather real-world evidence to demonstrate biosimilar interchangeability. The ultimate goal is ensuring patients can access effective treatments.20. Ubier Gomez - University of Antioquia
20. Ubier Gomez - University of AntioquiaInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Este documento presenta información sobre biotecnológicos y biosimilares. Explica que los biosimilares no son genéricos ni copias idénticas de los biológicos originales debido a la complejidad de estas moléculas. Los biosimilares deben someterse a pruebas clínicas rigurosas para demostrar su eficacia y seguridad antes de su aprobación. La farmacovigilancia continua es fundamental para monitorear cualquier efecto adverso potencial de los biosimilares.19. Agnes Klein - Health Canada
19. Agnes Klein - Health CanadaInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Biosimilars are complex biologic drugs that are similar but not identical to innovative biologic reference products. Several key points are made:
- Biosimilars are regulated differently than small molecule generics due to biologics' larger size and more complex manufacturing processes.
- While some regulators may designate a biosimilar as interchangeable, decisions on substitution are made separately at a national or state level.
- Health Canada does not declare any drug interchangeable and leaves substitution decisions to provinces, whereas the FDA may designate a biosimilar interchangeable if it is biosimilar and switching poses no greater risk to patients.
- Automatic substitution is not recommended and interchangeability requires specifically designed clinical trials for each18. Raffaella Balocco - WHO
18. Raffaella Balocco - WHOInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document summarizes key points about the WHO International Nonproprietary Name (INN) Programme:
- The INN Programme assigns a single international nonproprietary name to pharmaceutical substances to ensure consistency worldwide and promote safe use of medicines globally.
- It aims to develop, establish, and promote international standards for naming pharmaceutical and biological products, including biotherapeutics.
- There is an ongoing discussion around developing a system for distinguishing biosimilar products through INN naming to promote unambiguous identification of reference products globally.17. Gino Grampp - Amgen
17. Gino Grampp - AmgenInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This document discusses the challenges of pharmacovigilance for biotherapeutic medicines. It notes that pharmacovigilance systems are developing at different rates globally, with inconsistent naming approaches for biotherapeutics. This can weaken signal detection. The document outlines five key challenges for biotherapeutics: 1) They are more complex and sensitive than small molecule drugs. 2) They can potentially elicit an immune response. 3) They can have complex pharmacology through multiple mechanisms. 4) Their properties are not fully predictable through preclinical studies. 5) They may follow different regulatory pathways than originator biologics like biosimilars. Comprehensive pharmacovigilance is needed due to potential safety differences between16. Malin Fladvad - Uppsala Monitoring Centre
16. Malin Fladvad - Uppsala Monitoring CentreInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document discusses the work of the Uppsala Monitoring Centre (UMC), the WHO Collaborating Centre for International Drug Monitoring. The UMC collects and analyzes safety reports on medicines from around the world to identify potential safety issues and communicates these to improve patient safety. It maintains the VigiBase database and WHO drug dictionaries to support pharmacovigilance. The presentation highlights UMC's role in monitoring biotherapeutics and biosimilars, including the number of reports received on various biologic medicines over time and by region. It also discusses challenges in analyzing reports that only include the active substance versus those that specify the trade name or reference product.14. Laura Castanheira - Anvisa
14. Laura Castanheira - AnvisaInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This presentation provides an overview of the regulation of biotherapeutic medicines in Brazil. It discusses the development of regulations from 1976 to the current 2010 regulation, which takes specific approaches for biosimilars. The presentation outlines the pathways for approval, including an individual development pathway requiring full clinical data and a comparability pathway allowing reduced data if comparability to an existing product is shown. It provides details on non-clinical and clinical report requirements and considerations for both pathways. Finally, it discusses guidelines, partnerships and future perspectives on biological product regulation in Brazil.More Related Content
Viewers also liked
IFPA Psoriasis Presentation
IFPA Psoriasis PresentationInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA Geneva Pharma Forum on 9 May 2014
Bringing Psoriasis into the Light
International Federation of Psoriasis Associations
Barbra BohannanIFPMA: From Manufacturing to the Vaccinee – the Complex Journey of a Vaccine
IFPMA: From Manufacturing to the Vaccinee – the Complex Journey of a Vaccine International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
David K. Robinson, Ph. D. Vice President, Biologics Head and Executive Director, Biologics and Vaccines CMC Regulatory Merck & Co, Inc.
Presenting on behalf of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) WCBP CASS, Washington DC, USA January 2014Session 4: Bejon Misra Partnership for Safe Medicines (PSM) INDIA /
Session 4: Bejon Misra Partnership for Safe Medicines (PSM) INDIA / International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanSession 4 Sabine Walser Council of Europe / Legal framework necessary for eff...
Session 4 Sabine Walser Council of Europe / Legal framework necessary for eff...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanManaement of Psoriasis in Low Income Countries
Manaement of Psoriasis in Low Income CountriesInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA Geneva Pharma Forum on 9 May 2014
Bringing Psoriasis into the Light
Presentation of Professor Mahira Hamdy El Sayed
Dermatology and Venereology, Ain Shams UniversitySession1: Patrick Deboyser, European Union
Session1: Patrick Deboyser, European UnionInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 1: Current Regulatory Landscape & Initiatives Against Fake Medicines
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanPeter Hotez, Baylor College of Medicine
Peter Hotez, Baylor College of MedicineInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
30 November 2016, Washington DC
IFPMA Assembly 2016: Global Health V.2.0 Challenges in a Changing WorldSession 2: Mike Rose, Johnson & Johnson / Serialization and Traceability GS1 ...
Session 2: Mike Rose, Johnson & Johnson / Serialization and Traceability GS1 ...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 2: Supply Chain Integrity
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanSession 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...
Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanBringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
Bringing Psoriasis into the Light, Kim kjoeller, Leo PharmaInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document discusses psoriasis, a chronic skin condition affecting over 125 million people worldwide. Psoriasis causes thickened, red, scaly skin patches that often itch and bleed. It can also cause joint pain and increase risks for other health issues. The document outlines pharmaceutical company efforts to develop new drug treatments for psoriasis, including topical treatments, biologics, and oral medications currently in clinical trials. It emphasizes the need for comprehensive care that coordinates treatment from specialists and considers patients' needs to best manage psoriasis as a chronic condition.Session 2: Scott Kammer, Rx360
Session 2: Scott Kammer, Rx360 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 2: Supply Chain Integrity
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanSession 3: Ivan Ho Pfizer / Counterfeit Medicines Threat to Patient Health an...
Session 3: Ivan Ho Pfizer / Counterfeit Medicines Threat to Patient Health an...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 3: Practices and Technologies for Prevention, Detection, Control and Monitoring of Fake Medicines
On 6th February 2015
At Taipei International Convention Center
Taipei, TaiwanViewers also liked (13)
IFPMA: From Manufacturing to the Vaccinee – the Complex Journey of a Vaccine
IFPMA: From Manufacturing to the Vaccinee – the Complex Journey of a Vaccine
Session 4: Bejon Misra Partnership for Safe Medicines (PSM) INDIA /
Session 4: Bejon Misra Partnership for Safe Medicines (PSM) INDIA /
Session 4 Sabine Walser Council of Europe / Legal framework necessary for eff...
Session 4 Sabine Walser Council of Europe / Legal framework necessary for eff...
Session 2: Mike Rose, Johnson & Johnson / Serialization and Traceability GS1 ...
Session 2: Mike Rose, Johnson & Johnson / Serialization and Traceability GS1 ...
Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...
Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...
Bringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
Bringing Psoriasis into the Light, Kim kjoeller, Leo Pharma
Session 3: Ivan Ho Pfizer / Counterfeit Medicines Threat to Patient Health an...
Session 3: Ivan Ho Pfizer / Counterfeit Medicines Threat to Patient Health an...
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...
Session 3: Fu-Wen Chang, nternational Federation of Pharmaceutical Wholesaler...
More from International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
13 carlo pini superior institute of italy
13 carlo pini superior institute of italyInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Latin Amercia Conference - Biotherapeutic Medicines
Sharing Experiences and Best Practices
Lima, Peru,
20 November 201315. Elki Sollenbring - Uppsala Monitoring Centre
15. Elki Sollenbring - Uppsala Monitoring CentreInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Wednesday, 20 November, 2013
Latin America Biotherapeutic Conference Day 221. Maurice Mayrides - Esperantra
21. Maurice Mayrides - EsperantraInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Maurice Mayrides discusses the importance of the patient voice in regulating biosimilars. He summarizes the value of biosimilars from different stakeholder perspectives including patients, clinicians, industry, and governments. While biosimilars offer potential cost savings and innovation, patients will only feel comfortable with interchangeability if regulations are sophisticated and harmonized internationally. Regulations must ensure safety, efficacy, and quality to gain patient trust especially in emerging markets and lower-resource countries. Continued advocacy is needed to refine regulations and gather real-world evidence to demonstrate biosimilar interchangeability. The ultimate goal is ensuring patients can access effective treatments.20. Ubier Gomez - University of Antioquia
20. Ubier Gomez - University of AntioquiaInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Este documento presenta información sobre biotecnológicos y biosimilares. Explica que los biosimilares no son genéricos ni copias idénticas de los biológicos originales debido a la complejidad de estas moléculas. Los biosimilares deben someterse a pruebas clínicas rigurosas para demostrar su eficacia y seguridad antes de su aprobación. La farmacovigilancia continua es fundamental para monitorear cualquier efecto adverso potencial de los biosimilares.19. Agnes Klein - Health Canada
19. Agnes Klein - Health CanadaInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Biosimilars are complex biologic drugs that are similar but not identical to innovative biologic reference products. Several key points are made:
- Biosimilars are regulated differently than small molecule generics due to biologics' larger size and more complex manufacturing processes.
- While some regulators may designate a biosimilar as interchangeable, decisions on substitution are made separately at a national or state level.
- Health Canada does not declare any drug interchangeable and leaves substitution decisions to provinces, whereas the FDA may designate a biosimilar interchangeable if it is biosimilar and switching poses no greater risk to patients.
- Automatic substitution is not recommended and interchangeability requires specifically designed clinical trials for each18. Raffaella Balocco - WHO
18. Raffaella Balocco - WHOInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document summarizes key points about the WHO International Nonproprietary Name (INN) Programme:
- The INN Programme assigns a single international nonproprietary name to pharmaceutical substances to ensure consistency worldwide and promote safe use of medicines globally.
- It aims to develop, establish, and promote international standards for naming pharmaceutical and biological products, including biotherapeutics.
- There is an ongoing discussion around developing a system for distinguishing biosimilar products through INN naming to promote unambiguous identification of reference products globally.17. Gino Grampp - Amgen
17. Gino Grampp - AmgenInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This document discusses the challenges of pharmacovigilance for biotherapeutic medicines. It notes that pharmacovigilance systems are developing at different rates globally, with inconsistent naming approaches for biotherapeutics. This can weaken signal detection. The document outlines five key challenges for biotherapeutics: 1) They are more complex and sensitive than small molecule drugs. 2) They can potentially elicit an immune response. 3) They can have complex pharmacology through multiple mechanisms. 4) Their properties are not fully predictable through preclinical studies. 5) They may follow different regulatory pathways than originator biologics like biosimilars. Comprehensive pharmacovigilance is needed due to potential safety differences between16. Malin Fladvad - Uppsala Monitoring Centre
16. Malin Fladvad - Uppsala Monitoring CentreInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document discusses the work of the Uppsala Monitoring Centre (UMC), the WHO Collaborating Centre for International Drug Monitoring. The UMC collects and analyzes safety reports on medicines from around the world to identify potential safety issues and communicates these to improve patient safety. It maintains the VigiBase database and WHO drug dictionaries to support pharmacovigilance. The presentation highlights UMC's role in monitoring biotherapeutics and biosimilars, including the number of reports received on various biologic medicines over time and by region. It also discusses challenges in analyzing reports that only include the active substance versus those that specify the trade name or reference product.14. Laura Castanheira - Anvisa
14. Laura Castanheira - AnvisaInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This presentation provides an overview of the regulation of biotherapeutic medicines in Brazil. It discusses the development of regulations from 1976 to the current 2010 regulation, which takes specific approaches for biosimilars. The presentation outlines the pathways for approval, including an individual development pathway requiring full clinical data and a comparability pathway allowing reduced data if comparability to an existing product is shown. It provides details on non-clinical and clinical report requirements and considerations for both pathways. Finally, it discusses guidelines, partnerships and future perspectives on biological product regulation in Brazil.9 Karin Heidenreich - Novartis
9 Karin Heidenreich - NovartisInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
This document provides an overview of biosimilars and their development process according to international guidance. It begins with definitions of biosimilars and their differences compared to generic small molecule drugs. It then describes the two key steps in biosimilar development: 1) Developing a highly similar product through extensive analytical comparison to the reference product, and 2) Confirming biosimilarity through a targeted clinical program. It reviews guidelines from the WHO, EMA, and FDA on evaluating biosimilarity and the need for analytical, nonclinical and clinical comparisons. The document aims to explain the rigorous process of demonstrating biosimilarity that biosimilar developers must undergo to obtain regulatory approval.12 Dr. Thomas Schreitmueller Roche
12 Dr. Thomas Schreitmueller RocheInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The document discusses the importance of selecting sensitive patient populations for clinical trials of biosimilar monoclonal antibodies to properly assess clinical similarity to the reference product. It provides examples of indications and populations that are more sensitive for detecting differences based on effect size, such as rheumatoid arthritis patients for assessing ACR20 response to anti-TNF antibodies. The document cautions that clinical trials must be designed appropriately to demonstrate equivalence or non-inferiority and should obtain data on relevant endpoints in sensitive populations as well as long-term safety and immunogenicity follow-up to justify extrapolation to other indications. It critiques examples of biosimilar clinical trials that failed to use a sensitive population or design.More from International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (11)
Recently uploaded
Acute Gout Care & Urate Lowering Therapy .pdf
In this document , the management of acute gout attacks and a description of urate lowering therapy is mentioned.
Know the difference between Endodontics and Orthodontics.
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Ageing, the Elderly, Gerontology and Public Health
Challenges associated with ageing from a public health perspective
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
Pollen and Fungal allergy: aeroallergy.pdf
Pollen and Fungal allergy: aeroallergy.pdfChulalongkorn Allergy and Clinical Immunology Research Group
Pollen and Fungal allergy
Presented by Chaloemchai Chumsaengchotsakul, MD.
June 14, 2024Pharmacology of 5-hydroxytryptamine and Antagonist
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montrealSENSORY NEEDS B.SC. NURSING SEMESTER II.
Sensation is the neurological process by which we become aware of surrounding environment.
Nano-gold for Cancer Therapy chemistry investigatory project
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Fallopian tube blockage may cause female infertility. For treatment, herbal medicine Fuyan Pill can be a solution.
What is Obesity? How to overcome Obesity?
Obesity is a chronic complex disease defined by excessive fat deposits that can impair health.
Patellar Instability: Diagnosis Management
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
biomechanics of running. Dr.dhwani.pptx
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
Recently uploaded (20)
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and Synonyms
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers